This will be replaced by the player.

Posts Tagged ‘Proteonomix’

FFHL, PROT, MYRX, CRWE, MOSY Stock Market Report from CRWEFinance.com

Thursday, January 6th, 2011

drstock-2-3

signup3m

 

 

prot_logo_200x72

Proteonomix (PROT.OB) notes the favorable similarity between technology involved in the Cephalon, Inc. (CEPH) transaction with Australian company Mesoblast Limited.

Michael Cohen, the Company’s founder and CEO stated, “We applaud the transaction between Cephalon and Mesoblast and take this opportunity to note that our StromaCel® bone marrow derived stem cell technology attacks similar medical problems with a different approach.”

Mr. Cohen continued, “Our StromaCel® technology is also designed to treat damage to cardiac tissue caused by myocardial infarction (MI) and we are actively seeking funding to open clinics worldwide to treat MI patients. This technology was developed in conjunction with the University of Miami where bone marrow derived stem cells are undergoing Phase I trials. We are seeking joint venture partners to give effect to this strategy.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix. StromaCel, Inc.’s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

***************************

Crown Equity Holdings Inc. (OTCBB:CRWE) announced recently that it is expanding its business by opening another office in Pakistan. This office will be located in the city of Attock, Pakistan. This office will add an additional workforce of 25 associates to its CRWENewswire team, which will increase the company’s up to date news and world affairs from the Mid-East, Far East and Europe online news wires.

The new office in the city of Attock, as well as the office in Islamabad, will be managed by Zeeshan Shabbir.

Crown Equity Holdings is in the process of developing its Arabic language CRWENewswire site for news occurring in Pakistan and elsewhere around the world.

 

***************************

Fuwei Films (Holdings) Co., Ltd. (Nasdaq:FFHL) recently announced that management has become aware of a sharp increase in the Company’s stock price over the past three months, since the announcement of the settlement of the class action litigation against the Company on September 20.

Fuwei Films (Holdings) Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and distribution of plastic film using the biaxial oriented stretch technique, known as BOPET film (biaxially oriented polyethylene terephthalate).

***************************

Myrexis, Inc. (Nasdaq:MYRX) recently announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM). In previous Phase 2 studies, Azixa demonstrated potent, durable antitumor responses without any additive toxicity.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection.

***************************

MoSys, Inc. (NasdaqGM:MOSY) recently announced that Len Perham, President and Chief Executive Officer, and Jim Sullivan, Chief Fincial Officer, will present at the 13th Annual Needham Growth Stock Conference to be held at the New York Palace Hotel in New York, NY. Management is scheduled to present at 10:00 a.m. (Eastern Time) on Wednesday, January 12, 2011, and will available to meet with investors throughout the day. Portfolio managers and analysts who wish to meet with management at the conference should contact their Needham & Company, LLC representative or email conferences@needhamco.com.

MoSys, Inc. designs, develops, markets, and licenses embedded memory intellectual property (IP) used by the semiconductor industry and communications, networking, and storage equipment manufacturers.

 

 

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

 

drstbc

 

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services (which has expired) for Proteonomix, Inc. (PROT.OB)

 
Share/Bookmark
 
 
 

OC, PROT, NYX, BOB.V, ALL - Stock Update From DrStockPick.com!

Wednesday, January 5th, 2011

 

drstock-2-3

signup3m

 

 

prot_logo_200x72

Proteonomix (PROT.OB) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company’s addition to its Board of Directors. Proteonomix, Inc. is pleased to announce that Ian McNiece has been appointed to the Proteonomix Board of Directors.

In February, 2010, he was appointed to the Board of Directors of The Foundation for the Accreditation of Cellular Therapy (FACT). Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. It is a non-profit corporation co-founded by the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in cellular therapy field. The major objective of FACT is to promote high quality patient care and laboratory performance in the belief that a valid accreditation must assess both clinical and laboratory aspects.

In 2000, recognizing the global impact of cord blood banking and transplantation, FACT co-developed international standards for cord blood collection, processing, testing, banking, selection and release. In 2006, FACT collaborated to establish international standards in the field of cellular therapy by international teams of experts in cellular therapy and cord blood banking fields. The standards contain the minimum guidelines for facilities and individuals performing cellular therapy product transplantation, cord blood banking, or providing support services for such activities. On-site inspections are carried out by a team of inspectors who are qualified by training and experience, have attended inspector training and who have a working knowledge of FACT. The inspection process is quality-oriented and follows the FDA’s rules for current Good Tissue Practice.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

**************************************

http://pennyomega.com/img/bob.jpg

Global Hunter Corp. (TSX.V: BOB) (FSE:G5D) is pleased to announce that it recently completed a surface sampling program at La Corona de Cobre. The program was designed to collect surface samples from the numerous prospective shear zones. This will aid in the definition of drill targets to expand on the copper oxide mineralization.

The samples will be collected from outcrops along the entire strike lengths of the shears and have been shipped to ALS Chemex Labs in La Serena Chile for analysis. Results will be released as soon as is practical after they have been received.

These shear zones can be traced on surface for hundreds of metres, with the longest being Vino Fino, which has been mapped for over 6,000 metres. Local miners are currently extracting ore from several shear zones on the property and transporting it to Enami for processing.

The surface sample results in conjunction with previous geophysical work completed on the property, Global Hunter intends to prepare a multi-hole drill program on the shear zones scheduled to begin early 2011 as part of its ongoing evaluation of its Corona de Cobre project. In addition to sampling and drilling of the prospective shear zones at La Corona de Cobre mentioned above, The Company will continue its work on the Las Posadas resource over the coming months and will provide a summary of its progress as information becomes available.

Global Hunter’s flagship project is the La Corona de Cobre property, located 70 kilometres north of La Serena, Chile, along the Pan American Highway, within the coastal belt of the Andean Cordillera. The NI 43-101-compliant resource contains 225 million pounds of copper oxide. In addition, the Company has its Rabbit South molybdenum project in south-central British Columbia, Canada.

For More Information Go To: www.globalhunter.ca

**************************************

The Allstate Corporation (NYSE:ALL) announced the launch of Drive Wise, a voluntary program that rewards safe and low-mileage Illinois drivers with discounts of up to 30 percent. The company plans to expand Drive Wise to other states as early as Q2 2011. Consumers can learn more and sign up for the program by contacting their local Allstate agent.

The Allstate Corporation, through its subsidiaries, engages in the personal property and casualty insurance business, as well as in the life insurance, retirement, and investment products business in the United States and Canada.

**************************************

NYSE Euronext, Inc. (NYSE:NYX) will host an investor day for the professional investment community on Tuesday, March 8, 2011, at the New York Stock Exchange, 11 Wall Street, New York, NY. The day’s schedule will commence with opening remarks at 8:30a.m.will expected to conclude at approximately 12:30p.m. Presenters at the conference will include Duncan L. Niederauer, Chief Executive Officer, NYSE Euronext, and other members of the company’s executive management team.

NYSE Euronext, through its subsidiaries, provides securities listing, trading, market data products, and software and technology services worldwide. The company offers products and services in cash equities, futures, options, swaps, exchange-traded products, bonds, market data, and commercial technology solutions to issuers, investors, financial institutions, and market participants.

**************************************

Owens Corning (NYSE:OC) announced that it has reached a definitive agreement with Boral Industries Ltd. to sell its Masonry Products business. The divestiture will be in two stages. Owens Corning will sell a 50 percent stake in its Masonry Products business to Boral Industries Ltd. for $45 million at closing. The Masonry Products business will then be operated jointly until early 2014. At that time, Owens Corning will sell its remaining 50 percent stake for $45 million and may receive additional proceeds dependent upon 2013 financial performance.

Owens Corning, through its subsidiaries, provides composite and building materials systems worldwide. It operates in two segments, Composites and Building Materials.

************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

 

drstbc

 

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services (which has expired) for Proteonomix, Inc. (PROT.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from Global Hunter Corp. (TSX Venture Exchange (TSX.V:BOB) and the Frankfurt Stock Exchange (FSE:G5D)) for 30 (thirty) days of advertising, as well as for assistance in becoming a fully reporting publicly trading Bulletin Board company.

 
Share/Bookmark
 
 
 

Proteonomix, Inc. (PROT) Updates Its Global Activities; Ian McNiece Joins Board of Directors

Tuesday, January 4th, 2011

MOUNTAINSIDE, NJ–(Marketwire - 01/03/11) - PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company’s addition to its Board of Directors. Proteonomix, Inc. is pleased to announce that Ian McNiece has been appointed to the Proteonomix Board of Directors effective today. Dr. McNiece, has served as Vice-President for Scientific Development and Chief Scientific Officer since November 11, 2009. He received his PhD in 1986 from the University of Melbourne undertaking his thesis work in studies of blood cell development at the Peter MacCallum Cancer Institute in Melbourne, Australia. He moved to the United States in July, 1986 to the University of Virginia as a postdoctoral fellow. In August, 1997 he was employed by Amgen, Inc, as a Research Scientist and then as a Laboratory Head. In September 1998, he left Amgen and moved to the University of Colorado as the Director of Research in the Bone Marrow Transplant Program. Subsequently, he joined JHU as a Professor of Oncology and Laboratory Director of the Graft Engineering Laboratory from January 2003 to May 2007. This laboratory is responsible for all processing of bone marrow, peripheral blood progenitor cell (PBPC) products and cord blood products for transplantation of cancer patients. He was actively involved in optimization of cellular grafts for patient treatment and the translation of basic research to clinical treatment. In July, 2007 he joined the Stem Cell Institute at U Miami as Director of the Experimental and Clinical Cell-Based Therapies and is presently Professor of Medicine at U Miami. Dr. McNiece on January 2, 2007 became a member of the Scientific Advisory Board and Chief Scientific Officer of Proteonomix.

In February, 2010, he was appointed to the Board of Directors of The Foundation for the Accreditation of Cellular Therapy (FACT). Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. It is a non-profit corporation co-founded by the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT) for the purposes of voluntary inspection and accreditation in cellular therapy field. The major objective of FACT is to promote high quality patient care and laboratory performance in the belief that a valid accreditation must assess both clinical and laboratory aspects.

In 2000, recognizing the global impact of cord blood banking and transplantation, FACT co-developed international standards for cord blood collection, processing, testing, banking, selection and release. In 2006, FACT collaborated to establish international standards in the field of cellular therapy by international teams of experts in cellular therapy and cord blood banking fields. The standards contain the minimum guidelines for facilities and individuals performing cellular therapy product transplantation, cord blood banking, or providing support services for such activities. On-site inspections are carried out by a team of inspectors who are qualified by training and experience, have attended inspector training and who have a working knowledge of FACT. The inspection process is quality-oriented and follows the FDA’s rules for current Good Tissue Practice.

Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted, “The elevation of Dr. McNiece to the Board will allow Ian to play a greater role in developing corporate policy especially as it relates to the development and procurement of Intellectual policy (’IP’). Further, as BOD member, Dr. McNiece will have the ability to influence the development of other business strategies that affect the current portfolio of IP.”

Dr. McNiece stated, “I look forward to serving on the Board of Directors and expediting the development and commercialization of our current and future products, especially as this relates to the Proteonomix portfolio of clinical applications.”

About Proteonomix, Inc.:

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements:
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact:

Constellation Asset Management, LLC
415-524-8500

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwenewswire.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services (which has expired) for Proteonomix, Inc. (PROT.OB)

 
Share/Bookmark
 
 
 

Businesses Attempting Perfection - DrStockPick.com - Xl, PWRM, NXY, PBI

Friday, October 15th, 2010

drstock-2-3

signup3m

power3

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, reported that it delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”

Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which Power3 has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, for which Power3 is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

XL Group plc (NYSE: XL) and Breed’s Hill Insurance Agency, Inc., a specialized Managing General Underwriter, disclosed a new joint underwriting agreement to provide General Liability (GL) and Property coverages for multi-unit apartment buildings, condominium associations, and mixed-use real estate risks primarily in the New England market.

XL Group plc, through its subsidiaries, provides insurance and reinsurance coverages to industrial, commercial, and professional firms, insurance companies, and other enterprises worldwide. The company operates in three segments: Insurance, Reinsurance, and Life Operations. The Insurance segment provides property, casualty, professional liability, environmental liability, aviation and satellite, marine and offshore energy, equine, fine art and specie, and excess and surplus lines, as well as other insurance coverages, including program business.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Nexen Inc. (NYSE: NXY) announced that in the first quarter of this year, Nexen made a significant discovery in the deep-water Gulf of Mexico at Appomattox, located in Mississippi Canyon blocks 391 and 392. Drilling activities resulted in an oil discovery with excellent reservoir quality following an exploration well and two appraisal sidetracks. Based on the results of this drilling, Nexen’s estimate of recoverable contingent resource for this discovery exceeds 250 million barrels of oil equivalent with upside potential. Once drilling resumes in the Gulf of Mexico, Nexen plans to further appraise Appomattox.

Nexen Inc. operates as an independent energy company worldwide. Nexen operates through three segments: Oil and Gas, Energy Marketing, and Chemicals. The Oil and Gas segment explores for, develops, and produces crude oil, natural gas, and related products.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Pitney Bowes Inc. (NYSE: PBI) and DASCOM Americas revealed a new agreement in which Pitney Bowes will provide on-site repair and maintenance services to DASCOM Americas’ channel partners and customers in the U.S. With the agreement, Pitney Bowes will be the preferred services provider for DASCOM Americas in the U.S. and offer comprehensive on-site installation, repair and maintenance for DASCOM Americas products. The collaboration will enable DASCOM Americas to offer its customers convenient and efficient service options for the repair and maintenance of their equipment.

Pitney Bowes Inc. provides mail processing equipment and integrated mail solutions in the United States and internationally. Pitney Bowes offers a suite of equipment, supplies, software, and services for end-to-end mailstream solutions, which enable its customers to optimize the flow of physical and electronic mail, documents, and packages across their operations.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares as compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc. had received an additional amount of 2,000,000 shares of free trading stock for 60 days of media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). Each advertising commitment has now expired.

 
Share/Bookmark
 
 
 

Companies Heading Up - RSH, UDR, PROT, IRM - DrStockPick.com

Friday, October 15th, 2010

drstock-2-3

signup3m

 

 

prot_logo_200x72

Proteonomix, Inc. (OTC.BB:PROT) reported that Proteonomix has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases. Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.

Michael Cohen, President of Proteonomix, stated: “This is another step in the development of our intellectual property and getting StromaCel into the commercial market. The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

RadioShack Corp. (NYSE: RSH) celebrated its 75th anniversary of listing on the New York Stock Exchange. Julian C. Day, chairman and CEO of RadioShack Corp., commemorated the landmark event by visiting the trading floor and ringing The Opening Bell(SM) at the NYSE. “It’s a privilege to mark this occasion, and I do so on behalf of all the people who have played a role in moving this business forward through the decades. Together, we have helped RadioShack to reach a historic milestone that relatively few businesses ever achieve,” Mr. Day Said.

RadioShack Corporation engages in the retail sale of consumer electronic goods and services through its RadioShack store chain and non-RadioShack branded kiosk operations.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

UDR, Inc. (NYSE: UDR), a leading multifamily real estate investment trust (REIT), disclosed that W. Mark Wallis, senior executive vice president, plans to retire at the end of the year, after 10 years with UDR. Wallis will serve in a consultant role with UDR throughout 2011. During his time at UDR, Wallis, 60, helped establish a strong management team that is well prepared to carry out the company’s vision of providing high quality apartment homes and creating long-term shareholder value in the process. During his tenure with UDR, Wallis managed over $10 billion in real estate transactions.

UDR, Inc. formerly United Dominion Realty Trust, Inc., operates as a self-administered equity real estate investment trust (REIT). It owns, acquires, renovates, develops, and manages middle-market apartment communities. UDR targets young professionals, blue-collar families, single parent households, older singles, immigrants, and non related parties.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Iron Mountain Inc. (NYSE: IRM), an information management services company, revealed that the press announcement of its third quarter 2010 financial results is scheduled to be released before market hours on Thursday, October 28, 2010. A conference call has been scheduled to discuss the results and a taped replay of the conference call will be available shortly after the end of the call.

Iron Mountain Incorporated provides information management and related services for various media in North America, Europe, Latin America, and the Asia Pacific. It offers records management, data protection and recovery, and information destruction services.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).

 
Share/Bookmark
 
 
 
  • Site Translator:
Exclusive Videos



Hot stocks to watch!

Petroleo Brasileiro SA - PBR

Cleantech Transit, Inc. - CLNO.OB

SPDR S&P 500 ETF - SPY

Corning Inc - GLW

Direxion Shs Etf Tr - FAZ

Micron Technology Inc - MU

Starbucks Corp - SBUX

Crown Equity Holdings Inc. - CRWE.OB

Sprint Nextel Corp - S

Seagate Technology Plc - STX

iShares MSCI Emerging Markets Index ETF - EEM

JPMorgan Chase & Co - JPM

Gilead Sciences Inc - GILD

Sirius XM Radio Inc - SIRI

Baidu Inc - BIDU

Direxion Shs Etf Tr - FAS

Tellabs, Inc - TLAB

Brocade Communications Systems Inc - BRCD

Hewlett-Packard Co - HPQ

AT&T Inc - T

iShares Down Jones U.S. Real Estate Index - IYR

Applied Materials Inc - AMAT

 
 
Live With Dr.StockPick
Coming Soon
 
 

 

Follow Dr Stock Pick at
PennyOmega.com Vision

Every success must begin with a vision. If you can see it, you can achieve it.